論文題目
腎性尿崩症における Vasopressin V2 受容体の変異の同定と解析
指導教員 藤田 敏郎 教授
東京大学大学院医学系研究科
平成 19年4月入学
医学博士課程
内科学専攻
間中 勝則
以下本文
Inactivating mutations of V2 vasopressin receptor result in X－linkedcongenital nephrogenic diabetes insipidus（NDI），causing renal resistance tothe antidiuretic hormone，AVP．Although many mutations cause thecomplete loss of protein expression and thus complete phenotype，someunique mutations cause partial phenotype may suggest how the GPCRswork normally．In two families showing partial NDI，which had beenoriginally diagnosed as psychogenic polydipsia，we have identified two V2receptor mutations，S333del and Y128S and analyzed them together withother mutations．Both mutant V 2 receptors，when expressed in COS－7 cells， showed partial defect in vasopressin－stimulated cAMP accumulation．They predominantly showed intracellular localization with diminished cell－surface
expression. Inhibition of internalization by dominant negative dynamin or addition of 362 X mutation to V2 receptor mutations did not rescue their localization and function. Non-peptide V2 receptor antagonists partially rescued membrane localization and basal function of these V2 receptor mutants although they inhibited basal activity of wild type V2 receptor. These results suggest that partial loss of function of S333del and Y128S mutant V2 receptors results from defective membrane localization rather than constitutive internalization. These results also suggest that V2 receptor antagonists show protean agonism, serving as pharmacological cheperon to inactivating V2 receptor mutants and yet serving as inverse agonists to wild type receptors. If we could develop V2 receptor ligands that can restore membrane localization of V2 receptor mutants but do not inhibit agonist action or work as agonists by themselves, they might become useful drugs for investigating receptor kinesis and for treating NDI.

